Form 4: Stoke Therapeutics CMO Sells Shares Post-Vesting

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported the acquisition of 10,000 common shares from vested performance stock units and subsequent sales totaling 5,358 shares, primarily for tax obligations and a 10b5-1 plan.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported changes in his beneficial ownership of common stock.
• On December 3, 2025, Ticho acquired 10,000 shares of common stock at a price of $0, resulting from the vesting and settlement of performance stock units.
• Following this acquisition, Ticho's beneficial ownership was 25,156 shares.
• On December 4, 2025, Ticho disposed of 1,373 shares at a weighted average price of $30.7635 and 323 shares at a weighted average price of $31.3164. These sales were mandated by the Issuer to satisfy tax withholding liabilities related to restricted stock unit vesting.
• On December 5, 2025, Ticho disposed of 1,673 shares at a weighted average price of $31.3304, also for tax withholding liabilities.
• Additionally, on December 5, 2025, Ticho sold 1,989 shares at a weighted average price of $31.3453, executed pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
• After all reported transactions, Ticho's beneficial ownership stands at 19,798 shares of common stock.
• The performance stock units represent a contingent right to receive one share of common stock upon settlement, with half of the award vesting on December 3, 2024, and the remainder vesting on December 3, 2025.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving the vesting of equity awards and subsequent sales for tax purposes and a pre-arranged trading plan. These are common occurrences and do not indicate a significant positive or negative shift in the company's fundamentals or outlook.

Positives

• The vesting of 10,000 performance stock units indicates continued service and compensation for the Chief Medical Officer, aligning management's interests with shareholders.

Negatives

• Insider sales, even for tax purposes or pre-arranged plans, can sometimes be perceived negatively by the market, though these are routine transactions.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions, specifically the vesting of equity awards and subsequent sales for tax obligations and a pre-arranged trading plan. Such transactions are common across all industries for executives receiving equity-based compensation and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in insider ownership, with a portion of shares sold to cover tax liabilities and another portion under a pre-arranged trading plan. This is generally not expected to have a significant direct impact on shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing details routine insider transactions, including the vesting of equity awards and subsequent sales for tax obligations and a pre-arranged 10b5-1 plan. These transactions are common and do not typically signal a change in the company's fundamental outlook or warrant a significant shift in investment strategy based solely on this report. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter an existing investment thesis.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Sale, Equity Vesting, Chief Medical Officer, Barry Ticho, 10b5-1 Plan, Performance Stock Units